Intralesional allogeneic adipose-derived stem cells application in chronic diabetic foot ulcers
The major strength of this study is that it is the first single-center study evaluating the safety and outcomes after a single dose of intralesional allogeneic adipose-derived mesenchymal stem cells (ADMSCs) application.
"In conclusion, we observed that intralesional allogeneic ADMSCs injection is an effective and safe treatment modality in the treatment of relatively low-grade DFUs without infection in the long term. Satisfactory outcomes in wound healing, lower amputation and recurrence rates may be obtained with the injection of allogeneic ADMSCs when added to the standard treatment. Further randomized controlled and double-blind studies with a greater number of
participants are needed to determine the optimal application of allogeneic ADMSCs injections."
E. Uzun, et al., Intralesional allogeneic adipose-derived stem cells application in chronic diabetic foot ulcer: Phase I/2 safety study, Foot Ankle Surg (2020), https://doi.org/10.1016/j.fas.2020.08.002